Reference | Jacobs 2009 | Akagi 2008 | Channick 2006 | Hoeper 2003 | Mathai 2007 | Hoeper 2004 |
---|---|---|---|---|---|---|
Baseline therapy | ERA + PDE5i | Pr | ERA | Pr | ERA | None |
Add-on therapy | Pr | ERA | Pr | ERA | PDE5i | ERA |
Prostacyclin analogue | intravenous epoprostenol and subcutaneous treprostinil | intravenous epoprostenol | inhaled treprostinil | oral beraprost and inhaled iloprost | NA | NA |
Treatment dose | 10-20 ng/kg/min subcutaneous treprostinil, 38.4 end of observation. 6-8 ng/kg/min intravenous epoprostenol, 16.2 end of observation | 62.5 mg bosentan twice daily | 6 on 30 mcg inhaled treprostinil 4 daily 6 on 45 mug 4 daily. | 62.5 mg bosentan twice daily, increased to 125 mg twice daily after 4 weeks. | 20 mg sildenafil (up to 100 mg included) once daily | 62.5 mg bosentan twice daily, increased to 125 mg twice daily after 4 weeks. |
Patients at end of study | 10 | 7 | 11 | 20 | 25 | 9 |
Duration | 16 weeks | 1 year | 12 weeks | 6 months | 12 weeks | 3 months |
Change 6MWD | 41 (38) | 3 (23) | 67 (45) | 58 (9.6) | 20 (28) | 57 (35) |
Baseline 6MWD | 387 (30) | 392 (16) | 339 (26) | 346 (23.7) | 265 (19) | 346 |
Age | 37 | 32 | 51.2 | 46 | 56.2 | 39 |
Sex (% male) | 0.19 | 0.13 | 0.09 | 0.30 | 0.04 | 0.22 |
STATUS | 3 | 2 | 3 | 3.2 | 3.1 | 3.1 |
PVR | 957.8¶ | 776 | 744 | 1147 | 928 | 1549 |